Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,222.00
Bid: 2,221.00
Ask: 2,223.00
Change: 44.00 (2.02%)
Spread: 2.00 (0.09%)
Open: 2,196.00
High: 2,222.00
Low: 2,182.00
Prev. Close: 2,178.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

27 Sep 2017 07:00

RNS Number : 8921R
Halma PLC
27 September 2017
 

Halma plc

 

Trading Update

 

27 September 2017

 

Trading Update

 

Halma, the leading safety, health and environmental technology group today releases its scheduled Trading Update, relating to trading for the period from 2 April 2017.

 

Halma made good progress in line with the Board's expectations. The improved rates of organic constant currency revenue and profit growth achieved in the second half of the last financial year have continued into the current year. Order intake was ahead of revenue and also ahead of the same period last year.

 

There was widespread growth geographically, with organic constant currency revenue increases in all major regions. Asia Pacific maintained strong growth, with good progress in the UK and Mainland Europe and a steady performance in the USA.

 

The Environmental & Analysis sector performed particularly well, benefitting from strong growth in Asia Pacific and the re-organisation in its Life Science and Research business during the first half of last year.

 

The improved performance achieved by the Process Safety sector in the second half of last year continued. Market diversification and rising demand from the US onshore energy market both contributed to significant growth over the prior year.

 

The Infrastructure Safety sector continued to achieve good growth as greater investment in new product development in recent years contributed towards increasing demand from Asia Pacific and Mainland Europe.

 

The Medical sector also achieved solid revenue growth, although profitability was lower due to increased investment in new product development and sales resources.

 

In August 2017, we announced the acquisitions of Cardios for an initial consideration of R$50m (£12.1m) and CASMED for $4.5m (£3.4m). Both businesses strengthen our Medical sector's blood pressure monitoring technology base, with Cardios also being Halma's first acquisition in Brazil. The integration of both businesses is progressing well.

 

Our M&A pipeline strengthened during the period. We continue to search for businesses in, or adjacent to, all four sectors and the additional sector resources added during 2016 have improved both the quantity and quality of our opportunities.

 

Cash generation was good and the Group's financial position remains strong.

 

The results for the half year ending 30 September 2017 will be released on 21 November 2017.

 

 

 

 

For further information, please contact:

 

Halma plc Tel: +44 (0)1494 721111

Andrew Williams, Chief Executive

Kevin Thompson, Finance Director

 

MHP Communications Tel: +44 (0)20 3128 8100

Rachel Hirst/Andrew Jaques

 

 

Notes:

 

1.

This Trading Update is based on unaudited management accounts information and has been prepared solely to provide additional information to the shareholders of Halma plc. It should not be relied on by any other party, for other purposes. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

 

2.

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBLGDCUDDBGRL
Date   Source Headline
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change
30th Nov 20235:28 pmRNSPDMR Shareholding
22nd Nov 20234:36 pmRNSDirector Declaration
20th Nov 20237:00 amRNSAcquisition
16th Nov 20237:00 amRNSHalf Year Results
25th Oct 20237:00 amRNSAcquisitions
3rd Oct 202310:50 amRNSDirector/PDMR Shareholding
27th Sep 202312:28 pmRNSHolding(s) in Company
25th Sep 20231:00 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSTrading Update
4th Aug 20237:00 amRNSAcquisition
31st Jul 20233:00 pmRNSDirector/PDMR Shareholding
24th Jul 20239:00 amRNSDirectorate Change
20th Jul 20233:51 pmRNSResult of AGM
30th Jun 20239:00 amRNSDirector/PDMR Shareholding
28th Jun 20233:00 pmRNSDirector/PDMR Shareholding
22nd Jun 20233:58 pmRNSAnnual Financial Report
15th Jun 20237:00 amRNSFull Year Results
30th May 20237:11 amRNSDirector Declaration
12th May 20238:00 amRNSCompletion of acquisition
5th May 20237:00 amRNSAcquisition
28th Mar 20237:00 amRNSAcquisition
16th Mar 20237:00 amRNSTrading update
1st Mar 20233:39 pmRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSAcquisition
12th Jan 20237:00 amRNS2022 AGM – Voting Results Update Statement
29th Nov 202212:42 pmRNSDirector/PDMR Shareholding
17th Nov 20227:00 amRNSHalf Year Results
11th Nov 20227:00 amRNSHalma appoints new Chief Financial Officer
6th Oct 20227:00 amRNSAcquisition
3rd Oct 20224:38 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSAcquisition
22nd Sep 20227:00 amRNSTrading Statement
28th Jul 20223:01 pmRNSDirector/PDMR Shareholding
21st Jul 20223:33 pmRNSResult of AGM
4th Jul 20223:38 pmRNSDirector/PDMR Shareholding
29th Jun 20229:54 amRNSDirector/PDMR Shareholding
23rd Jun 20225:50 pmRNSAnnual Financial Report
17th Jun 20224:41 pmRNSDirector/PDMR Shareholding
16th Jun 20227:01 amRNSGroup Chief Executive succession
16th Jun 20227:00 amRNSFinal Results
14th Apr 20227:00 amRNSAcquisition
7th Apr 20227:00 amRNSSite Visit
28th Mar 20221:59 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSTrading update
21st Feb 20227:00 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.